Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M

Revenue: As of FY2025 Q2, the actual value is USD 3.752 M, missing the estimate of USD 3.796 M.

EPS: As of FY2025 Q2, the actual value is USD -0.62.

Segment Revenue

• Net product sales for Q2 2025 were $3.8 million, a 47% increase from $2.6 million in Q2 2024.

Operational Metrics

• Net loss for Q2 2025 was - $1.6 million, or - $0.62 per share, compared to - $1.3 million, or - $0.93 per share, in Q2 2024.
• Selling, general, and administrative expenses increased to $5.1 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to higher profit-sharing with EVERSANA and increased professional fees.
• Total operating expenses for Q2 2025 were $5.3 million, up from $3.8 million in Q2 2024.

Cash Flow

• Net cash used in operating activities for the six months ended June 30, 2025, was - $1.6 million, compared to - $3.4 million for the same period in 2024.
• Cash and cash equivalents as of June 30, 2025, were $12.1 million.

Unique Metrics

• New prescribers increased by 20% year-over-year, indicating growing clinical adoption of GIMOTI.
• Refill rates remained steady at approximately 70%.

Outlook / Guidance

• Evoke Pharma confirms its full-year 2025 net product sales guidance of approximately $16 million, representing up to a 60% increase over 2024. This guidance reflects trends in prescription growth, refill rates, and expanded pharmacy access, while considering external factors such as macroeconomic conditions and supply chain constraints.